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For more than 60 years, we have known that the incidence of certain common human cancers increases
with age. Recently in Science, Tomasetti and Vogelstein (2015) refined this model by providing a potential
explanation, arguing that early randommutational events within individual stem cells of regenerating organs
may underlie this correlation.It is well recognized that some human
cancers (e.g., colon) are muchmore com-
mon than others (e.g., bone). Additionally,
most cancers show a striking increase in
incidence with advancing age. What is
it about the biology and temporality of
the transforming process that underpins
these two observations? For more than
three decades, we have focused upon
two main factors—genetic predisposition
and environmental exposure. A recent
study from Tomasetti and Vogelstein
puts forward a third factor providing a
provocative explanation for this (Toma-
setti and Vogelstein, 2015; Tomasetti
et al., 2013). Through the meta-analysis
of published data on cancer incidence,
as well as analyzing the dynamics of the
turnover of specific tissues, they uncover
a striking correlation between the normal
regenerative capacity of tissues (the cu-
mulative number of all stem cell divisions
per lifetime) and the lifetime risk of devel-
oping cancer. Since the regenerative ca-
pacity of a particular tissue is critically
dependent on both the number of stem
cells and how often they divide, the
authors ultimately show that this number
(total stem cell divisions) positively corre-
lates with the lifetime risk of developing a
particular cancer. Finally, the authors look
at this parameter in the context of a strong
environmental (smoking and lung cancer)
or inherited (mismatch repair deficiency or
APC mutation in colon cancer) risk fac-
tors. What they are attempting to do in
these instances is to tease apart how
much impact these additional risk cate-
gories contribute to the overall risk of can-
cer development. It is no surprise that in
both instances, the extra risk conferred
by these factors adds considerably to
the intrinsic risk due to the total numberof stem cell divisions in either the lung or
the colon. What is a surprise, however,
is that in other common human cancers
such as esophageal, pancreatic ductal,
and certain leukemias, the total number
of stem cell divisions in the relevant organ
system may contribute much more than
either inherited or environmental fac-
tors to overall risk of developing these
cancers.
Having set out the basic observation
and correlation, the authors speculate
that the accrual of somatic mutations in
a tissue starts within its stem cells. These
mutations arise because of the natural
error rate of normal DNA replication.
Therefore, the more rounds of genome
replication that a stem cell undergoes,
then the greater number of mutations
accumulate largely through stochastic
means. Although the majority of these
somatic mutations will be passengers,
occasionally, a key driver gene might be
altered leading to the emergence of
clonal dominance followed by further
mutations and eventual maturation into
cancer (Figure 1).
This provocative interpretation raises
some important and challenging ques-
tions for stem cell biology as a whole.
First, are there any direct studies that
would lend support to the authors’ propo-
sition? Recent work on the origin of acute
myeloid leukemia (AML) and the clonal
nature of blood production in the aged
population is in keeping with this theory.
Shlush et al. (2014) report that in some
AML patients the final leukemic blast cells
arose from hematopoietic stem cells
(HSCs) that had acquired a somatic muta-
tion in the DNMT3A gene (DNMT3AMut).
They further demonstrated that HSCs
harboring DNMT3AMut possessed signifi-Cell Stem Cell 16cantly better regenerative properties
compared to DNMT3A wild-type HSCs.
This important discovery was quickly fol-
lowed by a flurry of papers where individ-
ual blood from large cohorts of aged
humans was deep sequenced and the
nature of somatically acquired mutations
cataloged (Genovese et al., 2014; Jaiswal
et al., 2014). The most remarkable finding
in these studies was that in older cohorts,
a significant number of individuals
(18.4% at >90 years) showed common
somatic mutation profiles that reflected
clonal hematopoiesis. Mutations in three
genes (AXL1, TET2, and DNMT3A) were
commonly associated with the develop-
ment of clonal hematopoiesis. Since
these mutations were present in all blood
lineages of the same individual, the
authors concluded that they must have
originated in an HSC. Furthermore clonal
hematopoiesis was associated with an
adverse outcome with a proportion
of these individuals developing blood-
related cancers.
While the recent AML data supports
Tomasetti and Vogelstein’s interpretation,
there are some key considerations that
should also be taken into account. A limi-
tation of the paper is that the analysis was
limited to tissues for which data on their
regenerative cell pools was available.
In this regard, two important omissions
were breast and prostate cancer, which
both have significant genetic and environ-
mental components.
Another important consideration is the
authors’ contention that the intrinsic mu-
tation rate due to DNA replication is suffi-
cient to drive mutagenesis. This may be
so, but more careful consideration of the
etiology of these mutations may be war-
ranted. First, recent work has revealed, February 5, 2015 ª2015 Elsevier Inc. 111
Figure 1. Mutations and Cancer Risk
Tissues with a greater number of cumulative stem cell divisions (e.g., colon)
have an increased risk of accumulating mutations (in red), eventually resulting
in cancer.
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rate of mutation varies be-
tween the stomach, the small
bowel, and the large bowel.
This may in part reflect the
different rates of stem cell di-
vision along the gastrointes-
tinal tract (Behjati et al.,
2014). However, in addition
to a different number of muta-
tions, the nature of these
mutations also varies. The
concept that different tissues
have variation in the fre-
quency and more importantly
the nature of mutation is reca-
pitulated when the sequence
of human tumors is analyzed
(Alexandrov et al., 2013).
These different mutational
signatures are inconsistent
with the idea that intrinsic
errors of replication are the
sole driver of mutagenesis in
stem cells. Additionally, aged
HSCs accumulate damaged
DNA associated with defec-
tive DNA replication (Flachet al., 2014). Although mechanistically
unclear, this suggests that aged HSCs
may have an intrinsic defect in replicating
their own DNA that in itself may lead to
increased mutagenesis.
Finally, it is becoming apparent that
different stem cell pools may employ
unique genome maintenance strategies
in order to counteract sources of endo-
genous DNA damage that may be partic-
ular to their niche or their own meta-
bolic configuration (Garaycoechea et al.,
2012). This addiction of specific stem
cell pools to certain classes of DNA repair
is illustrated by the phenotypes observed
in humans defective in those specific DNA
repair processes. For example, human
patients who lack the Fanconi anemia
DNA repair pathway are at huge risk of
developing hematological cancers (Ga-
raycoechea and Patel, 2014). In contrast,
patients lacking mismatch repair are at
increased risk of developing colorectal112 Cell Stem Cell 16, February 5, 2015 ª201cancers. Taken together, these data sug-
gest that different tissue-specific stem
cells have particular DNA repair require-
ments, suggesting that they might be
exposed to different sources of endoge-
nous DNA damage. It is therefore plau-
sible that different patterns of mutation
occur in different tissues due to the repli-
cation of damaged DNA, in addition to
the unfaithful copying of the template
strand by DNA polymerase. These muta-
tions become dangerous and predispose
to cancer if they are further propagated.
Related to this, in certain situations an
unusual demand may be made on stem
cells in tissues. For example, the turn
over of the colonic epithelium is increased
in inflammatory bowel disease, which is
known to significantly increase the risk
of colon cancer. It will be very interesting
to see how Tomasetti and Vogelstein’s
model might be integrated in such
situations.5 Elsevier Inc.All in all, the hypothesis that
the lifetime number of stem
cell doublings might be a
major factor in cancer predis-
position is compelling; the
question now for the field of
stem cell biology is to under-
stand better how mutagen-
esis occurs and is limited in
these valuable cells.REFERENCES
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